Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Service Revenue				$ 1,740,855
Total Revenue				1,740,855
Operating expenses:
Research and development	621,927	936,196	3,135,413	1,730,337
General and administrative	1,187,035	680,077	4,475,642	4,263,265
Total operating expenses	1,808,962	1,616,273	7,611,055	5,993,602
Loss from operations	(1,808,962)	(1,616,273)	(7,611,055)	(4,252,747)
Other income (expense):
Interest expense, net	(445,363)	(331,459)	(1,400,249)	(1,615,233)
PPP loan forgiveness	253,347		253,347
Change in fair value of derivative on debt	145,449	49,992	239,278	60,504
Loss on debt conversion		(88,817)	(27,504)	(254,884)
Total other income (expense)	(46,567)	(370,284)	(935,128)	(1,809,612)
Net loss before non-controlling interests	(1,855,529)	(1,986,557)	(8,546,183)	(6,062,360)
Net loss attributable to non-controlling interests	(293,001)		(949,295)
Net loss attributable to Oncotelic Therapeutics, Inc.	$ (1,562,528)	$ (1,986,557)	$ (7,596,888)	$ (6,062,360)
Basic net loss per share attributable to common stock	$ (0.00)	$ (0.02)	$ (0.03)	$ (0.07)
Basic weighted average common stock outstanding	370,443,893	88,964,549	279,358,671	87,474,986